JMP keeps Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated at market outperform by JMP Securities analyst Adam Cutler. The company reported fourth-quarter 2005 loss-per-share results of $0.22, beating JMP's estimate of $0.28 and the Street consensus of $0.30. The analyst is reducing his Factive estimate to $36 million from $38 million and raising his Testim revenue estimate to $9.2 million from $8.8 million. Shares of the Waltham, Mass., pharmaceutical company were down 13 cents, or 5.96%, at $2.05 on volume of 1,413,769 shares versus the three-month running average of 606,275 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.